NEW YORK, Feb. 13 - Beckman Coulter and Specialty Laboratories have signed a cross-licensing agreement to develop multi-analyte assays for the Beckman Progressive microarray platform, the instrument manufacturer said on Wednesday.
Under the deal, Specialty Laboratories will have early access to Beckman Coulter's assay-development technology. Beckman will in turn have access to multi-analyte assays that Specialty may develop as a result.
Financial details of the arrangement were not disclosed.
The companies expect that testing services resulting from the collaboration may be available by the end of the year.
The Beckman technology will allow Specialty Laboratories to produce multiple analytical results from one sample incubation, Specialty Laboratories Chairman and CEO James Peter said in a statement.
Specialty Laboratories, based in Santa Monica, Calif., is a clinical reference laboratory that serves hospitals, labs, and physicians. The company also conducts R&D independently and in conjunction with biotech firms.